US 12,065,497 B2
Methods of treatment using CCR8 antibodies
Sandra Berndt, Hohen Neuendorf (DE); Christian Bertling, Wuppertal (DE); Pascale Buchmann, Leverkusen (DE); Philipp Ellinger, Düsseldorf (DE); Katharina Filarsky, Düsseldorf (DE); Matyas Gorjanacz, Berlin (DE); Sabine Hoff, Potsdam (DE); Nikolaus Pawlowski, Cologne (DE); Helge Roider, Hohen Neuendorf (DE); Beatrix Stelte-Ludwig, Wülfrath (DE); Mark Trautwein, Wülfrath (DE); Ernst Weber, Langenfeld (DE); Uwe Gritzan, Leverkusen (DE); Oliver von Ahsen, Berlin (DE); Christian Votsmeier, Cologne (DE); Wiebke Maria Nadler, Langenfeld (DE); Patrick Jones, Oakland, CA (US); Pedro Paz, Hercules, CA (US); Su-Yi Tseng, San Francisco, CA (US); and Phaik Lyn Oh, Emeryville, CA (US)
Assigned to Bayer Aktiengesellschaft, Leverkusen (DE)
Filed by Bayer Aktiengesellschaft, Leverkusen (DE)
Filed on Apr. 22, 2022, as Appl. No. 17/727,220.
Application 17/727,220 is a division of application No. 17/358,841, filed on Jun. 25, 2021, granted, now 11,427,640, issued on Aug. 30, 2022.
Claims priority of provisional application 62/705,608, filed on Jul. 7, 2020.
Claims priority of provisional application 62/705,434, filed on Jun. 26, 2020.
Claims priority of application No. 20205426 (EP), filed on Nov. 3, 2020.
Prior Publication US 2022/0363768 A1, Nov. 17, 2022
Int. Cl. A61K 39/395 (2006.01); A61K 47/68 (2017.01); C07K 14/715 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/2866 (2013.01) [A61K 47/6849 (2017.08); C07K 14/7158 (2013.01); A61K 2039/505 (2013.01); A61K 47/6803 (2017.08); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 2317/33 (2013.01); C07K 2317/41 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01); C07K 2319/03 (2013.01); G01N 33/57492 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A method for treatment of a tumor characterized by activated CCR8-expressing Treg cells or CCR8-expressing tumor cells comprising administering an effective amount of an isolated anti-CCR8 antibody or antigen-binding fragment thereof to a patient in need thereof; wherein the isolated anti-CCR8 antibody or antigen-binding fragment comprises six CDR sequences wherein each CDR has an amino acid sequence set forth in one of (a) to (r):
a. SEQ ID NO:420, SEQ ID NO:421, SEQ ID NO:422, SEQ ID NO:424, SEQ ID NO:425 and SEQ ID NO:426,
b. SEQ ID NO:600, SEQ ID NO:601, SEQ ID NO:602, SEQ ID NO:604, SEQ ID NO:605 and SEQ ID NO:606,
c. SEQ ID NO:618, SEQ ID NO:619, SEQ ID NO:620, SEQ ID NO:622, SEQ ID NO:623 and SEQ ID NO:624,
d. SEQ ID NO:661, SEQ ID NO:662, SEQ ID NO:663, SEQ ID NO:665, SEQ ID NO:666 and SEQ ID NO:667,
e. SEQ ID NO:681, SEQ ID NO:682, SEQ ID NO:683, SEQ ID NO:685, SEQ ID NO:686 and SEQ ID NO:687,
f. SEQ ID NO:703, SEQ ID NO:704, SEQ ID NO:705, SEQ ID NO:707, SEQ ID NO:708 and SEQ ID NO:709,
g. SEQ ID NO:723, SEQ ID NO:724, SEQ ID NO:725, SEQ ID NO:727, SEQ ID NO:728 and SEQ ID NO:729,
h. SEQ ID NO:743, SEQ ID NO:744, SEQ ID NO:745, SEQ ID NO:747, SEQ ID NO:748 and SEQ ID NO:749,
i. SEQ ID NO:763, SEQ ID NO:764, SEQ ID NO:765, SEQ ID NO:767, SEQ ID NO:768 and SEQ ID NO:769,
j. SEQ ID NO:783, SEQ ID NO:784, SEQ ID NO:785, SEQ ID NO:787, SEQ ID NO:788 and SEQ ID NO:789,
k. SEQ ID NO:803, SEQ ID NO:804, SEQ ID NO:805, SEQ ID NO:807, SEQ ID NO:808 and SEQ ID NO:809,
l. SEQ ID NO:827, SEQ ID NO: 828, SEQ ID NO: 829, SEQ ID NO: 831, SEQ ID NO:832 and SEQ ID NO:833,
m. SEQ ID NO:847, SEQ ID NO: 848, SEQ ID NO: 849, SEQ ID NO: 851, SEQ ID NO:852 and SEQ ID NO:853,
n. SEQ ID NO:867, SEQ ID NO: 868, SEQ ID NO: 869, SEQ ID NO: 871, SEQ ID NO:872 and SEQ ID NO:873,
o. SEQ ID NO:887, SEQ ID NO: 888, SEQ ID NO: 889, SEQ ID NO: 891, SEQ ID NO:892 and SEQ ID NO:893,
p. SEQ ID NO:907, SEQ ID NO: 908, SEQ ID NO: 909, SEQ ID NO: 911, SEQ ID NO:912 and SEQ ID NO:913,
q. SEQ ID NO:927, SEQ ID NO: 928, SEQ ID NO: 929, SEQ ID NO: 931, SEQ ID NO:932 and SEQ ID NO:933, and
r. SEQ ID NO:947, SEQ ID NO: 948, SEQ ID NO: 949, SEQ ID NO: 951, SEQ ID NO:952 and SEQ ID NO:9531,
and further wherein the treatment occurs by anti-CCR8 antibody induced depletion of the activated CCR8-expressing Treg cells or CCR8-expressing tumor cells.